Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

TG103

A Study of TG103 Injection in Overweight/Obese Subjects With Type 2 Diabetes

CSPC Baike (Shandong) Biopharmaceutical Co · Phase 2 · Status n/r · Enrollment 208

NCT05063253

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
TG103, 15 mgn/rn/rn/rn/r
TG103, 22.5 mgn/rn/rn/rn/r
TG103, 30 mgn/rn/rn/rn/r
Placebon/rn/rn/rn/r

Not shown

  • TG103, 15 mg: endpoint not reported
  • TG103, 22.5 mg: endpoint not reported
  • TG103, 30 mg: endpoint not reported
  • Placebo: endpoint not reported